MAPT and Alzheimer disease: Thus, adiponectin receptor signaling appears to enhance LTP in models with amyloid pathology (e.g., the 5xFAD model), as well as in the 3xTg‐AD model with both amyloid and tau pathology [16], an effect we demonstrate is AMPK‐dependent.